Examples of 64Cu-labeled antibodies for PET imaging are trastuzumab (breast cancers expressing human epidermal growth factor receptor 2 or HER2, in clinical trials) (Sampath et al. 2010; ClinicalTrials.gov 2012), 12A8 (c-kit expressing tumors) (Yoshida et al. 2011), etaracizumab (antibody against human αvβ3 integrin) (Cai et al. 2006), cetuximab (targeting EGFR-epidermal growth-factor receptor expressing tumors) (Li et al. 2008). This evidence concerns the gene EGFR and breast carcinoma.